- Home
- JRS vs PBYI Comparison
JRS vs PBYI Comparison
Compare JRS & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRS
- PBYI
- Stock Information
- Founded
- JRS 2001
- PBYI 2010
- Country
- JRS United States
- PBYI United States
- Employees
- JRS N/A
- PBYI N/A
- Industry
- JRS Finance/Investors Services
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- JRS Finance
- PBYI Health Care
- Exchange
- JRS Nasdaq
- PBYI Nasdaq
- Market Cap
- JRS 231.7M
- PBYI 263.4M
- IPO Year
- JRS N/A
- PBYI N/A
- Fundamental
- Price
- JRS $8.07
- PBYI $5.09
- Analyst Decision
- JRS
- PBYI Strong Buy
- Analyst Count
- JRS 0
- PBYI 1
- Target Price
- JRS N/A
- PBYI $7.00
- AVG Volume (30 Days)
- JRS 86.6K
- PBYI 622.4K
- Earning Date
- JRS 01-01-0001
- PBYI 11-06-2025
- Dividend Yield
- JRS 8.87%
- PBYI N/A
- EPS Growth
- JRS N/A
- PBYI 59.87
- EPS
- JRS N/A
- PBYI 0.74
- Revenue
- JRS N/A
- PBYI $211,995,000.00
- Revenue This Year
- JRS N/A
- PBYI N/A
- Revenue Next Year
- JRS N/A
- PBYI N/A
- P/E Ratio
- JRS N/A
- PBYI $6.97
- Revenue Growth
- JRS N/A
- PBYI N/A
- 52 Week Low
- JRS $5.95
- PBYI $2.32
- 52 Week High
- JRS $8.00
- PBYI $6.12
- Technical
- Relative Strength Index (RSI)
- JRS 52.09
- PBYI 50.68
- Support Level
- JRS $7.85
- PBYI $4.80
- Resistance Level
- JRS $8.12
- PBYI $6.12
- Average True Range (ATR)
- JRS 0.09
- PBYI 0.41
- MACD
- JRS 0.00
- PBYI -0.03
- Stochastic Oscillator
- JRS 55.56
- PBYI 37.86
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.